Main Menu

Dr Maggie Cheang

Team Leader

The alt text
Dr Maggie Cheang develops genomics classifiers for tumour subtypes and determines their clinical utility to predict sensitivity of each tumour type to therapeutic agents in phase II and III clinical trials. She co-invented the 50 genes-based classifier for the intrinsic subtypes of breast cancer, commonly known as PAM50. Team: ICR-CTSU Integrative Genomic Analysis in Clinical Trials
020 8722 4552 ORCID 0000-0001-5718-2501


Dr Maggie Cheang grew up in Vancouver, Canada and obtained her PhD in Pathology and Laboratory Medicine under the supervision of Professor Torsten Nielsen from the University of British Columbia in Canada. She then received a prestigious Canadian Cancer Society/Terry Fox Foundation Postdoctoral Fellowship to train with Professor Charles Perou, a pioneer in identifying subtypes of breast cancer, at the Lineberger Comprehensive Cancer Center at the University of North Carolina, US.

Her work has been instrumental in the identification and validation of multiple clinically recognised biomarkers, one of which has been implemented into clinical practice guidelines.

Her research achievements have been internationally recognised by numerous awards, grants and memberships. She was a Merit Award recipient at the American Society of Clinical Oncology Meeting in 2011 and received a Clinical Science Scholar Scholarship at the CTRC-AACR San Antonio Breast Cancer Symposium in 2011.

Dr Cheang was also a recipient of a Career Development Award for Junior Faculty funded by ReThink Breast Cancer Canada in 2011–12; two Novartis Oncology Young Canadian Investigator Awards (2011, 2008); and a National Cancer Institute of Canada Traveling Award for senior graduate students (2007–08).

She consults on several trial management and translational research committees for phase II and III trials. As a mark of her standing in the field, she currently serves as an Associate Editor of BMC Cancer, and a Steering Committee member for the National Cancer Research Institute (NCRI) CM-Path Clinical Trials Pathology Advisory Group (CT-PAG) and leads the Biomarker reference subgroup within the Cellular Molecular – Pathology Initiative (Discovery work stream).

Dr Cheang co-invented the 50 genes-based classifiers for the breast cancer intrinsic subtypes. This assay, commonly known as PAM50, is currently licensed by NanoString® Technologies as Prosigna and is integrated into multiple international clinical practice guidelines including the German Association of Gynecological Oncology (AGO), St. Gallen International Breast Cancer, European Society for Medical Oncology (ESMO), National Comprehensive Cancer Network (NCCN) and American Society of Clinical Oncology (ASCO) Clinical Practice Guidelines for clinical subtype classification in breast cancer. 

Outside of work, she enjoys playing piano and snowboarding.